Description
Canine Factor VIII Paired Antibody Set
Affinity’s Canine Factor VIII Paired Antibody Set consists of matched capture and detecting antibodies that have been titrated and optimized for use in sandwich style ELISA assays. The product as provided contains sufficient capture and detecting antibodies for four full 96-well microplates and contains a detailed protocol sheet containing directions for use, recipes for solutions and sources for additional materials required. This Canine Factor VIII Paired Antibody Set is intended to facilitate the end user in establishing an “in-house” immunoassay for research purposes only and must not be used for diagnostic applications. Assay validation is the responsibility of the end user.
Product Code: CFVIII-EIA
Supplied Materials:
- Capture Antibody (CFVIII-EIA-C): One yellow-capped vial containing 0.4 ml of polyclonal affinity purified anti-Canine Factor VIII antibody for coating plates.
- Detecting Antibody (CFVIII-EIA-D): One red-capped tube containing 0.4 ml of peroxidase conjugated affinity-purified polyclonal anti-Canine Factor VIII antibody for detection of captured Canine FVIII.
Product Datasheet: Canine Factor VIII (F8, FVIII) Matched Pair Antibody Set for ELISA - cFVIII-EIA
Description of Factor VIII (FVIII)
Factor VIII (formerly referred to as antihemophilic globulin and Factor VIII:C) is a large glycoprotein (320 kDa) that circulates in plasma at approximately 200 ng/ml. Synthesized in the liver, the majority of Factor VIII is cleaved during expression, resulting in a heterogeneous mixture of partially cleaved forms of FVIII ranging in size from 200-280 kDa. The FVIII is stabilized by association with von Willebrand Factor to form a FVIII-vWF complex required for the normal survival of FVIII in vivo (t1/2 of 8-12 hours).
F.VIII is a pro-cofactor that is activated through limited proteolysis by thrombin. In this process F.VIIIa dissociates from vWF to combine with activated Factor IX, calcium and a phospholipid surface where it is an essential cofactor in the assembly of the Factor X activator complex. Once dissociated from vWF, FVIIIa is susceptible to inactivation by activated Protein C and by non-enzymatic decay.
Hemophilia A is a congenital bleeding disorder resulting from an X-chromosome-linked deficiency of FVIII. The severity of the deficiency generally correlates with the severity of the disease. Some Hemophiliacs (~10%) produce a FVIII protein that is partially or totally inactive. The production of neutralizing antibodies to FVIII also occurs in 5-20% of Hemophiliacs 1-3.
References and Reviews:
- Lollar P, Fay PJ, Fass DN; Factor VIII and Factor VIIIa. Methods in Enzymology, 222, pg 122, 1993.
- Hoyer, LW, Wyshock EG, Colman RW, in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 109-133, J.B. Lippincott Co., Philadelphia, 1994.
- Pittman DD, Kaufman RJ. Structure-Function Relationships of Factor VIII Elucidated through Recombinant DNA Technology. Thromb. Haemostas. 61:161-165, 1989.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
二抗
抗体组合
免疫组化
免疫沉淀
ELISA
ELISPOT
流式
同型对照
酪胺信号放大
免疫对照/血清/阻断/封闭
Western Blot免疫印迹
免疫缓冲剂/固定/透化
细胞/组织裂解物
细胞核裂解物
细胞裂解物
组织抽提物
转染细胞裂解物
CBA蛋白定量
链霉亲和素
抗体纯化
英 ['aisəutaip]
美 ['aisəutaip]
n. 同形像;
同形像统计图
阴性对照(Isotype Control):非特异荧光的强弱取决于抗体浓度、单克隆荧光抗体特异性和纯度,应与试验管抗体相对应。在多色分析时,同型对照应与其它抗体同时使用,以避免补偿造成的误差
血小板体外活化试验:使用正常人活化标本作为阳性质控;使用正常人未活化标本作为阴性质控
血小板自身抗体检测:使用含有已知血小板抗体的血清与血小板孵育,作为阳性质控;使用不含血小板抗体的血清与血小板孵育,作为阴性质控
血小板表面抗原缺失:如巨血小板症血小板表面CD42a/CD42b缺失,血小板无力症血小板表面gpIIb/IIIa,即CD41/CD61缺失或异常。使用正常人标本做阳性对照,抗体的同型对照做阴性对照